About us

Prof. Dr. Ralf C. Bargou currently serves as the Director at the Comprehensive Cancer Center (CCC) Mainfranken and holds the Chair for Translational Oncology at the University Hospital Würzburg. He is a renowned expert for his significant contributions to immuno-oncology, particularly in the development of T-cell engaging bi-specific antibodies. His instrumental role in the creation of the bispecific antibody blinatumomab earned him the Paul Martini Prize in 2009 and the Inventor of the Year Award in 2016. He also developed targeted therapies for measurable residual disease (MRD) in acute lymphatic leukemia (ALL).

‍

Prof. Dr. Gernot Stuhler is an entrepreneur and Adjunct Professor at University of Würzburg heading a research group focused on T cell-engaging antibody derivatives and exploring combinatorial immune-oncology strategies. In previous roles, he served as a senior physician at the Würzburg University Hospital and as Chief Physician at the German Clinic for Diagnostics (DKD) in Wiesbaden, Germany. Professor Stuhler was trained in Immunology at the Max-Planck-Institute for Biology and Immunogenetics in Tübingen, Germany and at the Dana Farber Cancer Institute, Harvard Medical School, in Boston, USA.

‍

Dimitrios Tzachanis, MD, PhD, is a Professor of Medicine and the Clinical Director of the BMT Division at UC San Diego He specializes in treating patients with cancers of the blood and lymph system at the joint UC San Diego Health / Sharp HealthCare Blood and Marrow Transplantation Program with a focus on autologous and allogeneic stem cell transplantation and chimeric antigen receptor (CAR) T-cell therapy. He has published more than sixty peer-reviewed articles in medical journals such as the New England Journal of Medicine, the Lancet, Blood, Nature Immunology, among others.

‍

Prof. Dr. med. Matthias Miederer is a renowned nuclear medicine physician leading the Department of Translational Imaging in Oncology at the National Center for Tumor Diseases (NCT/UCC), a joint center of excellence serving the University Hospital Dresden, the Medical Faculty at Dresden’s University of Technology, the German Cancer Research Centre DKFZ, and the Helmholtz-Association’s HDZR Center. In his role, Professor Miederer is paving the way for new radiopharmaceuticals into clinical practice in therapeutic and diagnostic applications. Prior to his current role, Professor Miederer worked at the University Medical Center of the University of Mainz, the Charité in Berlin, at the Klinikum rechts der Isar in Munich and as a Research Fellow at the Memorial Sloan Kettering Cancer Center.

‍